Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
Effect of Rimonabant on Hand Function in Patients With Spinal Cord Injury
Key facts
- Who runs it
- Sinfatin S.L
- Where
- Spain1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 8 people, planned
- Started
- 13 May 2026
- Expected to end
- Aug 2027
- Type of study
- Interventional
- Treatments tested
- Rimonabant
- Record updated
- 21 October 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Age between 18 and 75 years
- At least 2 months since spinal cord injury
- Cervical spinal cord injury (C1-C8) with AIS A-D
- Muscle strength should be within a range of 5 to 40 points on the UEMS score
- Capacity to provide informed consent
Who cannot take part
- History of severe psychiatric disorders, major depression or prior suicide attempts
- Treatment with anticoagulants or strong CYP3A4 inhibitors or inducers (inhibitors such as ketoconazole, itraconazole, ritonavir, telithromycin, clarithromycin, or nefazodone, and inducers such as rifampicin, phenytoin, phenobarbital, carbamazepine, or St. John's Wort)
- Participation in another clinical trial with pharmacological intervention within the month prior to enrolment
- Fertile men or women who cannot guarantee the use of highly effective contraceptive methods, as defined by the European HMA-CTFG guidelines-i.e., those with a failure rate of less than 1 % per year when used consistently and correctly (1); A woman is considered fertile if she is physiologically capable of becoming pregnant, from menarche until postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A woman is considered postmenopausal after spontaneous amenorrhea for at least 12 consecutive months with no alternative medical cause. An elevated follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to support the diagnosis in women not using hormonal contraception or hormone replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is not sufficient; Acceptable highly effective contraceptive methods include:; Combined hormonal contraception (containing estrogen and progestogen) associated with ovulation inhibition, administered orally, vaginally, or transdermal; Progestogen-only hormonal contraception associated with ovulation inhibition (oral, injectable, or implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner: provided this is the participant's sole sexual partner and the vasectomy has been medically confirmed as successful; Sexual abstinence: refraining from heterosexual intercourse during the entire treatment and follow-up period
- Uncontrolled hypothyroidism, or a history of severe bone, liver, or kidney disease
- Known allergy to rimonabant or any of the excipients used
- Any other condition that, in the opinion of the investigator, makes the subject's participation in the study unrecommended, such as severe heart failure or uncontrolled diabetes
- Contraindications for transcranial magnetic stimulation (TMS), such as metal implants in the head, pacemakers, epileptic seizures in the last two years, or other implanted electronic devices
- High suicide risk assessed by C-SSRS
- Body Mass Index (BMI) > 40 kg/m²
- Pregnancy or breastfeeding
- Inability to attend hospital visits
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an one arm study to be conducted in spinal cord injury patients. The goal of this clinical trial is to learn if rimonabant improves hand motor and performance function in patients with cervical spinal cord injury. It will also learn about the safety of rimonabant.
Read full original descriptionShow less
Participants will: Take 5 mg of rimonabant every day for 90 days. Visit the clinic once every 15-30 days for checkups and tests.
The group in the trial
- TreatmentTreatment being tested
This arm will receive two tablets of rimonabant 2.5 mg (total of 5 mg), once daily for 90 days
Treatment: Rimonabant
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Exploratory Study on the Effect of Rimonabant on Hand Function in Patients With Spinal Cord Injury (RIMOHANDOPEN)
- Record updated
- 21 October 2026